Joel Greenblatt's JAZZ Position Overview
Joel Greenblatt (via Gotham Asset Management, LLC) currently holds 61,200 shares of Jazz Pharmaceuticals plc (JAZZ) worth $10.4 M, representing 0.04% of the portfolio. First purchased in 2014-Q1, this long-term strategic position has been held for 42 quarters.
Based on 13F filings since 2013, Joel Greenblatt has maintained a long-term strategic position in JAZZ, representing a significant commitment to this investment thesis. Largest addition occurred in Q4 2015, adding 159,289 shares. Largest reduction occurred in Q2 2016, reducing 92,215 shares.
Analysis based on 13F filings available since 2013 Q2
Joel Greenblatt's Jazz Pharmaceuticals plc (JAZZ) Holding Value Over Time
Track share changes against reported price movement
Quarterly Jazz Pharmaceuticals plc (JAZZ) Trades by Joel Greenblatt
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +10,008 | Add 19.55% | 61,200 | $170.00 |
| Q3 2025 | -17,280 | Reduce 25.24% | 51,192 | $131.80 |
| Q2 2025 | +18,077 | Add 35.87% | 68,472 | $106.12 |
| Q1 2025 | +35,304 | Add 233.94% | 50,395 | $124.15 |
| Q4 2024 | -5,942 | Reduce 28.25% | 15,091 | $123.15 |
| Q3 2024 | +15,033 | Add 250.55% | 21,033 | $111.41 |
| Q2 2024 | +3,140 | Add 109.79% | 6,000 | $106.73 |
| Q1 2024 | -963 | Reduce 25.19% | 2,860 | $120.42 |
| Q4 2023 | -20,149 | Reduce 84.05% | 3,823 | $123.00 |
| Q3 2023 | -5,220 | Reduce 17.88% | 23,972 | $129.44 |
| Q2 2023 | +1,756 | Add 6.40% | 29,192 | $123.97 |
| Q1 2023 | +3,492 | Add 14.58% | 27,436 | $146.33 |
| Q4 2022 | +11,998 | Add 100.44% | 23,944 | $159.31 |
| Q3 2022 | +11,946 | New Buy | 11,946 | $133.27 |
| Q3 2021 | -1,614 | Sold Out | 0 | $0.00 |
| Q2 2021 | -10,350 | Reduce 86.51% | 1,614 | $177.82 |
| Q1 2021 | +10,163 | Add 564.30% | 11,964 | $164.41 |
| Q4 2020 | -241 | Reduce 11.80% | 1,801 | $164.91 |
| Q3 2020 | -19,521 | Reduce 90.53% | 2,042 | $142.51 |
| Q2 2020 | +21,563 | New Buy | 21,563 | $110.33 |
| Q1 2020 | -4,315 | Sold Out | 0 | $0.00 |
| Q4 2019 | -8,445 | Reduce 66.18% | 4,315 | $149.25 |
| Q3 2019 | -10,864 | Reduce 45.99% | 12,760 | $128.13 |
| Q2 2019 | +2,126 | Add 9.89% | 23,624 | $142.57 |
| Q1 2019 | -18,055 | Reduce 45.65% | 21,498 | $142.94 |
| Q4 2018 | -1,771 | Reduce 4.29% | 39,553 | $123.96 |
| Q3 2018 | +41,324 | New Buy | 41,324 | $168.13 |
| Q1 2018 | -17,170 | Sold Out | 0 | $0.00 |
| Q4 2017 | -16,887 | Reduce 49.58% | 17,170 | $134.65 |
| Q3 2017 | +3,749 | Add 12.37% | 34,057 | $146.25 |
| Q2 2017 | +17,692 | Add 140.23% | 30,308 | $155.50 |
| Q1 2017 | -68,801 | Reduce 84.50% | 12,616 | $145.13 |
| Q4 2016 | -71,834 | Reduce 46.87% | 81,417 | $109.03 |
| Q3 2016 | +47,847 | Add 45.39% | 153,251 | $121.48 |
| Q2 2016 | -92,215 | Reduce 46.66% | 105,404 | $141.31 |
| Q1 2016 | +12,658 | Add 6.84% | 197,619 | $130.55 |
| Q4 2015 | +159,289 | Add 620.48% | 184,961 | $140.56 |
| Q3 2015 | +22,107 | Add 620.11% | 25,672 | $132.79 |
| Q2 2015 | -7,309 | Reduce 67.22% | 3,565 | $176.16 |
| Q1 2015 | +10,874 | New Buy | 10,874 | $172.80 |
| Q2 2014 | -7,367 | Sold Out | 0 | $0.00 |
| Q1 2014 | +7,367 | New Buy | 7,367 | $138.73 |
Joel Greenblatt's Jazz Pharmaceuticals plc Investment FAQs
Joel Greenblatt first purchased Jazz Pharmaceuticals plc (JAZZ) in Q1 2014, acquiring 7,367 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt has held Jazz Pharmaceuticals plc (JAZZ) for 42 quarters since Q1 2014.
Joel Greenblatt's largest addition to Jazz Pharmaceuticals plc (JAZZ) was in Q4 2015, adding 184,961 shares worth $26 M.
According to the latest 13F filing for Q4 2025, Joel Greenblatt's firm, Gotham Asset Management, LLC, owns 61,200 shares of Jazz Pharmaceuticals plc (JAZZ), valued at approximately $10.4 M.
As of the Q4 2025 filing, Jazz Pharmaceuticals plc (JAZZ) represents approximately 0.04% of Joel Greenblatt's publicly disclosed stock portfolio, making it one of their key holdings.
Joel Greenblatt's peak holding in Jazz Pharmaceuticals plc (JAZZ) was 197,619 shares, as reported at the end of Q1 2016.